A prognostic score for postherpetic neuralgia in ambulatory patients

被引:55
作者
Meister, W
Neiss, A
Gross, G
Doerr, HW
Höbel, W
Malin, JP
von Essen, J
Reimann, BY
Witke, C
Wutzler, P
机构
[1] SmithKline Beecham Pharma GMBH, D-80804 Munich, Germany
[2] Univ Jena, Inst Antivirale Chemotherapie, D-99089 Erfurt, Germany
[3] Univ Frankfurt, Inst Med Virol, Zentrum Hyg, D-60596 Frankfurt, Germany
[4] Neurol Klin & Poliklin, Berufsgenossenschaftl Kliniken Bergmannsheil, D-44789 Bochum, Germany
[5] Univ Hamburg, D-20246 Hamburg, Germany
[6] Tech Univ Munich, Inst Stat & Epidemiol, D-81675 Munich, Germany
关键词
D O I
10.1007/BF02770836
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The main objective was to develop a scoring system for easy use by the physician in daily clinical practice in deciding the appropriate treatment for his herpes tester patient. Data from 635 patients who did not receive antiviral therapy were included in this analysis. Of these, 131 developed postherpetic neuralgia (PHN). Of the 29 variables tested univariately in this study, 15 showed a significant correlation with the incidence of PHN, but only six proved to contribute to the overall predictive power in the multivariate approach. Using two independent approaches, the model showed a very satisfactory performance in the validation sample. Patients without acute pain rarely developed PHN, In those with acute pain, being female, being over 50 years of age, having more than 50 lesions, having lesions of a hemorrhagic nature, having cranial or sacral localisation of the rash or having pain in the prodromal phase proved to be significant, multivariate factors, An easy-to-use scoring system used in a risk graph is proposed, These data should be useful in the individual treatment decision as well as in the design and analysis of therapeutic trials in herpes zoster.
引用
收藏
页码:359 / 363
页数:5
相关论文
共 15 条
[1]   VALACICLOVIR COMPARED WITH ACYCLOVIR FOR IMPROVED THERAPY FOR HERPES-ZOSTER IN IMMUNOCOMPETENT ADULTS [J].
BEUTNER, KR ;
FRIEDMAN, DJ ;
FORSZPANIAK, C ;
ANDERSEN, PL ;
WOOD, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1546-1553
[2]   POSTHERPETIC NEURALGIA IN OLDER PATIENTS - INCIDENCE AND OPTIMAL TREATMENT [J].
BOWSHER, D .
DRUGS & AGING, 1994, 5 (06) :411-418
[3]   Risk factors for postherpetic neuralgia [J].
Choo, PW ;
Galil, K ;
Donahue, JG ;
Walker, AM ;
Spiegelman, D ;
Platt, R .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (11) :1217-1224
[4]   THE COST OF TREATMENT FOR POSTHERPETIC NEURALGIA IN THE UK [J].
DAVIES, L ;
COSSINS, L ;
BOWSHER, D ;
DRUMMOND, M .
PHARMACOECONOMICS, 1994, 6 (02) :142-148
[5]  
DWORKIN RH, 1995, ANTIVIR RES, V26, pA344
[7]   THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36
[8]  
HARRELL FE, 1985, CANCER TREAT REP, V69, P1071
[9]  
Hope-Simpson R E, 1975, J R Coll Gen Pract, V25, P571
[10]  
KOST RG, 1994, NEW ENGL J MED, V335, P33